Acrivon Therapeutics, Inc..
ACRV.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Acrivon Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for cancer. The company utilizes its proprietary proteomics-based platform, Acrivon Predictive Precision Proteomics (AP3), to identify patients most likely to respond to its drug candidates. Acrivon's...Show More
Better Health for All
20
Acrivon Therapeutics, a biopharmaceutical company, is entirely devoted to developing precision medicines for cancer, with its entire business focused on health improvement. Its lead product candidate, ACR-368, demonstrates exceptional health benefits, achieving confirmed overall response rates (ORR) of 62.5% in OncoSignature-positive endometrial cancer patients
1
and 50% in the GYN total, significantly higher than the 14.7% ORR for second-line chemotherapy.
2
The median duration of response for ACR-368 is approximately 6 months
3
and has not yet been reached.
4
The company reports no revenue from products with negative health impacts. The safety record for ACR-368 indicates that adverse events were limited, predominantly transient, reversible, and mechanism-based hematological events,
5
with no long-lasting myelosuppression or severe non-hematological adverse events.
6
All of the company's R&D budget is allocated to health improvement, with Q1 2025 R&D expenses at $15.4 million,
7
and includes the development of ACR-2316 and the AP3 Interactome platform for drug design.
8
The company adheres to ethical requirements for clinical trials, including Good Clinical Practice (GCP), FDA Investigational New Drug (IND) regulations, and Institutional Review Board (IRB) approval.
9
Its privacy statement details data collection, use, and sharing.
10
The company's operations are not related to nutrition and food safety or addiction mitigation.
Fair Money & Economic Opportunity
0
Acrivon Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for cancer. The provided articles detail the company's initial public offering, private placement financing, financial results, and clinical trial progress for its drug candidates. The company's core business activities do not involve lending, insuring, moving, or storing money, nor does it offer financial services or products to consumers. Therefore, all Key Performance Indicators for the 'Fair Money & Economic Opportunity' value are not applicable to Acrivon Therapeutics' business model.
Fair Pay & Worker Respect
0
The CEO's total compensation is $2.00M, which is above the average of $656.30K for companies of similar size in the US market.
1
The company's overall average salary range is $79,714 to $312,029 per year.
2
Specific salary ranges include Chief Financial Officer at $235K - $421K annually, AI Engineer at $95K - $154K annually or $57 per hour, and Staff Accountant at $67K - $95K annually.
3
A compensation rating of -1/5 stars has been noted.
4
Fair Trade & Ethical Sourcing
0
The provided articles do not contain specific information or quantitative data relevant to Acrivon Therapeutics, Inc.'s fair trade and ethical sourcing practices. There is no evidence regarding fair-trade certification share, supplier audit frequency, substantiated forced or child labor incidents, supply chain traceability coverage, remediation speed for supplier violations, ethical clause coverage in supplier contracts, share of spend on high-risk materials, or supplier diversity spend. While the company's Code of Business Conduct and Ethics prohibits all forms of slavery, human trafficking, forced labor and child labor as defined by applicable law
1
and states that possible Code violations will be investigated promptly and with the highest degree of confidentiality that is possible under the specific circumstances
2
, these are not quantitative metrics of incidents or remediation speed for suppliers. The Code also mentions that procurement selects suppliers based exclusively on normal commercial considerations, such as quality, cost, availability, service and reputation, and not on the receipt of special favors
3
, but does not provide data on supplier diversity spend. Employees must return the signed acknowledgment form within ten (10) business days of receipt of the Code and on an annual basis as the Company may require
4
. The Audit Committee will review and reassess the adequacy of this Code at least annually
5
.
Honest & Fair Business
0
No information relevant to the 'Honest & Fair Business' ethical value, including regulatory fines, transparency benchmarks, whistle-blower policies, financial restatements, audit coverage, ESG controversies, complaint resolution times, board conflicts, anti-corruption policies, or third-party verification, was found in the provided article.
1
Kind to Animals
-40
Acrivon Therapeutics Inc. conducts pre-clinical studies on animals as part of its research and development process.
1
The company's Code of Business Conduct and Ethics states a commitment to conducting research ethically and in compliance with all applicable regulatory requirements, including standards related to animal welfare.
2
However, this policy does not prohibit or restrict animal testing, indicating that routine animal studies are permitted.
No War, No Weapons
0
Acrivon Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for cancer, including drug discovery programs and clinical trials for candidates like ACR-368 and ACR-2316.
1
The company's operations, including its Generative Phosphoproteomics AP3 platform, are entirely dedicated to drug development.
2
All provided articles explicitly state that the company's activities are not applicable to arms manufacturing, defense contracts, dual-use technologies, military sales, peacebuilding initiatives, or any other areas related to the 'No War, No Weapons' value.
3
Planet-Friendly Business
-20
The company has no specific regulatory actions, violations, fines, or compliance issues mentioned.
1
Acrivon Therapeutics, Inc. also participated in a neighborhood cleanup activity in Lund, Sweden, and Watertown, MA, in support of Earth Day.
2
Respect for Cultures & Communities
0
No specific data points or information relevant to the 'Respect for Cultures & Communities' ethical value, as defined by the provided KPIs, were found in the articles. The articles primarily focus on the company's biopharmaceutical operations, clinical trials, and a business partnership
1
. While a neighborhood cleanup activity in Lund, Sweden, and Watertown, MA, was mentioned
2
, it does not provide data for any of the specified cultural or community engagement metrics.
Safe & Smart Tech
-30
The company identified material weaknesses in its internal control over financial reporting related to a lack of design and maintenance of an effective control environment and effective controls in response to risks of material misstatement.
1
A formal incident response plan is in progress, and there is no formal vulnerability disclosure program.
2
The company reported no material cybersecurity incidents as of March 28, 2024, and no incidents of unauthorized data use.
3
Third-party service providers are contractually restricted from retaining, sharing, storing, or using personal information for purposes other than contracted services.
4
Users can request deletion of personal information and opt-out of marketing communications, with California residents having specific rights under Section 1798.83 of the California Civil Code.
5
The company references compliance with U.S. GAAP, SEC, FDA, cGMP, GDPR, and California Civil Code Section 1798.83.
6
Zero Waste & Sustainable Products
0
Acrivon Therapeutics has no mentioned regulatory actions, violations, fines, or compliance issues.
1